NextCure
NextCure: A biopharmaceutical firm innovating in immuno-oncology-based cancer treatments.
Founded
2015NextCure: A biopharmaceutical firm innovating in immuno-oncology-based cancer treatments.
NextCure, founded with a mission to revolutionize cancer treatment, is a biopharmaceutical company dedicated to discovering and developing next-generation immuno-oncology-based drugs. With a vision to become a global leader in novel immunomedicines, NextCure focuses on scientific innovation and addressing patient needs through its advanced therapeutic solutions. The company's primary market includes patients suffering from various forms of cancer, aiming to provide groundbreaking treatments that enhance the efficacy and safety of cancer care.
Notable figures associated with NextCure include key scientists and industry leaders who have significantly contributed to the field of immuno-oncology. The company has garnered attention and investment from prominent venture capital firms and strategic partners in the biopharmaceutical sector. Among its key achievements are the development of promising drug candidates currently undergoing clinical trials, demonstrating potential in improving patient outcomes. NextCure's impact lies in its commitment to transforming cancer treatment through cutting-edge research and innovative therapies, positioning itself as a significant player in the fight against cancer.
Companies similar to NextCure include INmune Bio, Curelab Oncology, Novita Pharmaceuticals and NextPoint Therapeutics.
NextCure was founded in 2015.
NextCure's headquarters is located in Beltsville, MD, US.
NextCure's most recent funding round was for $150M (USD) in November 2019.
As of Nov 12, 2019, NextCure has disclosed funding of $310M (USD). Undisclosed round amounts are excluded.
NextCure has 90 employees as of Feb 6, 2024.
NextPoint Therapeutics
nextpointtx.com
